Ensysce Biosciences (ENSC)
NASDAQ:ENSC
Want to see ENSC full AI Analyst Report?
Top Page
Ensysce Biosciences
(NASDAQ:ENSC)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.35
▼(-65.64% Downside)
Action:ReiteratedDate:04/09/26
The score is primarily weighed down by weak financial performance (collapsed revenue, deepening losses, and sustained cash burn). Technicals also reflect a broader downtrend with only neutral momentum signals. Recent financing provides some liquidity support but brings dilution risk, and valuation metrics offer little support given a non-meaningful P/E and no dividend.
Positive Factors
Proprietary MPAR overdose-protection technology
Breakthrough designation plus IRB approval to initiate Part 3 signal durable clinical progress for a novel overdose‑protection paradigm. If Part 3 confirms protective effects, MPAR can provide a lasting competitive moat, attract partners, and drive durable strategic value beyond short‑term trial outcomes.
Negative Factors
Revenue collapse and persistent losses
A collapse to near‑zero revenue and worsening operating losses indicate no durable commercial cash flow. Sustained negative profitability undermines self‑funding prospects, increases dependency on external capital, and limits the company’s ability to scale beyond clinical-stage programs absent successful partnerships or approvals.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary MPAR overdose-protection technology
Breakthrough designation plus IRB approval to initiate Part 3 signal durable clinical progress for a novel overdose‑protection paradigm. If Part 3 confirms protective effects, MPAR can provide a lasting competitive moat, attract partners, and drive durable strategic value beyond short‑term trial outcomes.
Read all positive factors
Ensysce Biosciences (ENSC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.45M
Dividend YieldN/A
Average Volume (3M)89.63K
Price to Earnings (P/E)―
Beta (1Y)1.59
Revenue Growth-2.75%
EPS Growth68.01%
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.75
Shares Outstanding9,277,819
10 Day Avg. Volume106,568
30 Day Avg. Volume89,627
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)<0.01
Price to Sales (P/S)0.46
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-1.16M
Enterprise Value/Revenue-790.20K
Enterprise Value/Gross Profit2.36M
Enterprise Value/Ebitda854.34K
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.29
Revenue Forecast (FY)$2.50M
Ensysce Biosciences Business Overview & Revenue Model
Company Description
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin A...
How the Company Makes Money
Ensysce Biosciences is a clinical-stage company and, based on publicly available information, does not have established, recurring commercial product revenue. As a result, any current or historical revenue is primarily tied to non-product sources ...
Ensysce Biosciences Earnings Call Summary
Earnings Call Date:Mar 15, 2024
(Q4-2023)
| % Change Since: |
Next Earnings Date:May 18, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted significant clinical achievements, including FDA breakthrough designations and successful trial completions, against a backdrop of financial challenges and reduced funding. The company is making progress toward its goals but needs additional funding to maintain momentum.Positive Updates
Significant Clinical Progress
2023 marked a year of exceptional clinical progress for Ensysce's next-generation analgesics, moving programs closer to commercialization.
Negative Updates
Limited Cash Reserves
The company ended 2023 with $1.1 million in cash and cash equivalents, highlighting the need for additional funding to initiate Phase III trials.
Read all updates
Q4-2023 Updates
Positive
Negative
Significant Clinical Progress
2023 marked a year of exceptional clinical progress for Ensysce's next-generation analgesics, moving programs closer to commercialization.
Read all positive updates
Company Guidance
During Ensysce Biosciences' Q4 2023 earnings call, the company provided detailed guidance on its advancements and future plans. Ensysce reported significant clinical progress with its next-generation opioid analgesics, focusing on the PF614 and PF614-MPAR products. The company completed five clinical trials for PF614, including a human abuse potential study and an analgesic efficacy study. Ensysce plans to initiate Phase III trials for PF614 in the second half of 2024, following FDA feedback. They also received breakthrough therapy designation for PF614-MPAR, highlighting its potential to prevent opioid overdose. Financially, Ensysce ended 2023 with $1.1 million in cash, supplemented by early 2024 warrant exercises and plans to raise additional funds before starting Phase III trials. The company’s R&D expenses decreased in 2023, totaling $7.6 million, with a focus on optimizing manufacturing and preparing for pivotal clinical trials.Ensysce Biosciences Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
22
Negative
Cash Flow
10
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.07M | 5.21M | 2.23M | 2.52M | 3.53M |
| Gross Profit | 0.00 | -2.01M | -5.36M | -17.31M | 3.53M |
| EBITDA | -10.15M | -6.73M | -10.72M | -24.22M | -25.93M |
| Net Income | -10.18M | -7.99M | -10.61M | -24.17M | -29.08M |
Balance Sheet | |||||
| Total Assets | 7.45T | 5.60M | 2.71M | 5.89M | 16.42M |
| Cash, Cash Equivalents and Short-Term Investments | 4.31T | 3.50M | 1.12M | 3.15M | 12.26M |
| Total Debt | 306.71B | 301.66K | 854.70K | 4.43M | 17.21M |
| Total Liabilities | 4.57T | 2.22M | 3.36M | 9.91M | 24.58M |
| Stockholders Equity | 3.21T | 3.71M | -322.86K | -3.71M | -7.88M |
Cash Flow | |||||
| Free Cash Flow | -7.81T | -7.50T | -10.78M | -17.89M | -8.24M |
| Operating Cash Flow | -7.81T | -7.50T | -10.78M | -17.89M | -8.24M |
| Investing Cash Flow | -123.64B | 0.00 | 0.00 | 4.50K | 0.00 |
| Financing Cash Flow | 8.74T | 9.88T | 8.76M | 8.77M | 20.31M |
Ensysce Biosciences Technical Analysis
Negative
1.01
Price Trends
0.50
Positive
0.82
Negative
1.50
Negative
Market Momentum
>-0.01
Positive
46.48
Neutral
41.66
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENSC, the sentiment is Negative. The current price of 1.01 is above the 20-day moving average (MA) of 0.54, above the 50-day MA of 0.50, and below the 200-day MA of 1.50, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 46.48 is Neutral, neither overbought nor oversold. The STOCH value of 41.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ENSC.
Ensysce Biosciences Risk Analysis
Ensysce Biosciences disclosed 48 risk factors in its most recent earnings report. Ensysce Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ensysce Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
ENSC
Ensysce Biosciences
0.37
-2.60
-87.51%
GLMD
Galmed Pharmaceuticals
0.57
-0.71
-55.47%
CYCN
Cyclerion Therapeutics
3.31
0.01
0.30%
SILO
Silo Pharma
0.44
-0.34
-43.33%
ALZN
Alzamend Neuro
1.14
-4.85
-80.95%
Ensysce Biosciences Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Ensysce Biosciences Secures $2 Million Private Financing
Positive
Apr 8, 2026
On April 6, 2026, Ensysce Biosciences closed a $2 million private offering under a 2025 securities purchase agreement, issuing Series B preferred stock convertible at $0.55 per share and accompanying warrants for up to 8,727,273 common shares, alo...
Executive/Board Changes
Ensysce Biosciences Announces Board Member Curtis Rosebraugh Resignation
Negative
Apr 3, 2026
On April 1, 2026, Ensysce Biosciences Inc. announced that board member Curtis Rosebraugh resigned from the company’s Board of Directors, effective the same day. Rosebraugh also stepped down from his role on the Nominating and Corporate Gover...
Regulatory Filings and Compliance
Ensysce Biosciences Corrects Series B Preferred Stock Designation
Neutral
Mar 23, 2026
On March 18, 2026, Ensysce Biosciences Inc. filed a Certificate of Correction with the State of Delaware to amend its Certificate of Designation of Series B Preferred Stock, which forms part of its Certificate of Incorporation. The filing corrects...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.